Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06632717
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 878
- Registration Number
- NCT06627647
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT06624059
- Locations
- 🇨🇱
Centro de Estudios Clínicos SAGA, Santiago, Chile
🇨🇱OrlandiOncología, Santiago, Chile
🇨🇱Inst. Nacional Del Cancer; Servicio de Oncologia Medica, Santiago, Chile
A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 680
- Registration Number
- NCT06623422
- Locations
- 🇺🇸
Beacon Cancer Care ( Site 0127), Post Falls, Idaho, United States
🇺🇸Thompson Cancer Survival Center ( Site 0168), Knoxville, Tennessee, United States
🇦🇺Tasman Oncology Research ( Site 2104), Southport, Queensland, Australia
A Phase 1b Study of TTF in Combination With Durvalumab and GemCis in BTC.
- Conditions
- Interventions
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-10-26
- Target Recruit Count
- 60
- Registration Number
- NCT06611345
- Locations
- 🇨🇳
Anhui Provincial Hospital, He Fei, China
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT06607185
- Locations
- 🇨🇳
Hsin-Chu Hospital, Hsin-chu, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇺🇸START Midwest, Grand Rapids, Michigan, United States
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 851
- Registration Number
- NCT06607393
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06594874
- Locations
- 🇨🇳
Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, China
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 33
- Registration Number
- NCT06591650
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
- Conditions
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 304
- Registration Number
- NCT06585189
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.